Pay in 4 interest-free payments of $6.17 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
Ozempic is paving the way for other GLP-1 drugs to treat conditions beyond kidney disease The FLOW trial results, along with the recent announcement that Wegovy is approved to reduce cardiovascular risk in people with obesity, are the latest indications that these drugs have benefits for conditions beyond their original intended treatment of type 2 diabetes
Yang W, Chen L, Ji Q, Liu X, Ma J, Tandon N, Bhattacharyya A, Kumar A, Kim KW, Yoon KH, et al: Liraglutide provides similar glycaemic control as glimepiride (both in combination with metformin) and reduces body weight and systolic blood pressure in Asian population with type 2 diabetes from China, South Korea and India: a 16-week, randomized, double-blind, active control trial(*)
Deep cleanse and brighten your skin with powerful ingredients like glutathione and niacinamide
Beyond glycemic effects, GLP-1 medications act on appetite regulation centers in the hypothalamus, promoting satiety and reducing hunger signals
US$ 27.56
US$ 21.79
US$ 23.71
